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Abstract: Directed enzyme prodrug therapy (DEPT) involves the delivery of a prodrug-activating
enzyme to a solid tumour site, followed by the subsequent activation of an administered prodrug. One
of the most studied enzyme–prodrug combinations is the nitroreductase from Escherichia coli (NfnB)
with the prodrug CB1954 [5-(aziridin-1-yl)-2,4-dinitro-benzamide]. One of the major issues faced by
DEPT is the ability to successfully internalize the enzyme into the target cells. NfnB has previously
been genetically modified to contain cysteine residues (NfnB-Cys) which bind to gold nanoparticles
for a novel DEPT therapy called magnetic nanoparticle directed enzyme prodrug therapy (MNDEPT).
One cellular internalisation method is the use of cell-penetrating peptides (CPPs), which aid cellular
internalization of cargo. Here the cell-penetrating peptides: HR9 and Pep-1 were tested for their
ability to conjugate with NfnB-Cys. The conjugates were further tested for their potential use in
MNDEPT, as well as conjugating with the delivery vector intended for use in MNDEPT and tested
for the vectors capability to penetrate into cells.
Keywords: nitroreductase; cell-penetrating peptide; prodrug therapy; darkfield imaging; nanoparticle
1. Introduction
The ability of materials to traverse the cell membrane is an important factor that has to be taken
into consideration when devising new medical treatments, requiring careful engineering to aid in
target cell uptake [1]. One of the most common forms of cell internalisation for molecular cargoes is
endocytosis. This process generally involves the formation of a vesicle surrounding the cargo, which is
then engulfed into the cell [2]. However, contents within the vesicle/endosome are often moved into
the endo-lysosomal system and are digested by acid hydrolases [3], rendering the cargo unusable for
its desired function. While this process is ideal for the uptake of nutrients and for the protection of
cells from antigens and toxins [4], it places a restriction on the therapeutic potential of novel therapies.
As such, it is important to discover novel approaches to efficiently enable target cell uptake, for which
cell-penetrating peptides (CPPs) represent one solution. CPPs are short peptides [5], often no more
than 30 amino acids in length [6]. Some CPPs possess the ability to pass through the cell membrane
and bypass the endosomal system, leaving cargoes intact [7]. It is often reported that there are several
properties that CPPs possess which enable them to efficiently pass into cells including being rich in
arginine and/or tryptophan residues [8–10] and possessing an overall positive charge at physiological
pH (~7.4) [10]. CPPs have already been shown to deliver a wide range of cargo into cells, including
nucleic acids [11], proteins [12], and nanoparticles [13].
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Directed enzyme prodrug therapy (DEPT) has previously been explored as an emerging form
of cancer treatment [14–20]. DEPT involves the delivery of a prodrug activating enzyme to a solid
tumour site, whereby after cell internalisation of the enzyme, a prodrug is then administered. One of
the most studied nitroreductase–prodrug combinations is nitroreductase from Escherichia coli (NfnB)
K-12, used in combination with the prodrug; CB1954 (5-(aziridine-1-yl)-2,4-dinitrobenzene). NfnB
converts CB1954 into either of the toxic 2’- or 4’-hydroxylamine derivatives, with this combination
having had a previous promising clinical outcome [21]. A range of strategies has been investigated to
directly deliver the enzyme or the encoding DNA to the target site, including viruses (VDEPT) [22,23],
antibodies (ADEPT) [24], peptides [25], and cationic lipids [26]. We have investigated a novel form
of DEPT that involves the incorporation of gold-coated superparamagnetic iron oxide nanoparticles
(AuMNP) as the delivery vehicle used to direct the enzyme to the tumour site, an approach termed
magnetic nanoparticle directed enzyme prodrug therapy (MNDEPT) [14,27]. A genetically modified
nitroreductase (NfnB-Cys) is conjugated to the surface of the nanoparticles [14,28] with conjugates
already proven to retain their prodrug reducing capability [29].
However, it has not yet been established whether the NfnB-Cys enzyme could be conjugated
to a CPP to enhance target cell uptake while retaining the reduction activity of CB1954. For these
experiments, two CPPs were chosen (HR9 and Pep-1) for conjugation to NfnB-Cys to assess cellular
uptake. Both CPPs have been shown to conjugate to peptides and protein structures, improving
internalization [30–33]. It was anticipated that the same improved internalization effect would be seen
with NfnB-Cys. The aims of this work were to assess conjugation of the CPPs onto NfnB-Cys, and
what effects this had on the enzymes activity and ability to reduce the CB1954 prodrug and cause cell
death. Further to this was to conjugate NfnB-Cys and the CPPs onto magnetic nanoparticles intended
for use in MNDEPT and again test for the ability for the NfnB-Cys to reduce CB1954 causing cell death.
2. Results
2.1. NfnB-Cys Expression and Purification
The NfnB enzyme is native to E. coli, but has been genetically modified by our research group to
contain six Cys-tags on the N-terminus of the protein [14]. The six Cys-tags aid the in the covalent
binding of the NfnB-Cys onto gold nanoparticles [14,28]. The gene was cloned into the pET28a(+)
vector, which added an additional six histidine residues after the Cys-tag for downstream purification
of the protein using metal ion affinity chromatography (IMAC). The SDS-PAGE gel of the purification
is presented in Figure 1, where the NfnB-Cys enzyme, eluted strongly between 300–800 mM imidazole,
with the highest concentration being the 500 mM fraction. Due to the high concentration of protein,
both monomeric and dimeric units were seen at ~27.3 kDa and 54.6 kDa. The NfnB-Cys enzyme was
obtained at a yield of up to 5 mg/mL.
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Figure 1. SDS-PAGE gel of the genetically modified nitroreductase (NfnB-Cys) purification using 
metal ion affinity chromatography (IMAC): lane 1, protein ladder (Thermoscientific PageRuler 15–
170 kDa); lane 2, flow-through after applying supernatant to column; lane 3, flow-through after 
applying 10 mM imidazole to column; lane 4, 50 mM imidazole eluent; lane 5, 100 mM imidazole 
eluent; lane 6, 200 mM imidazole eluent; lane 7, 300 mM imidazole eluent; lane 8, 500 mM imidazole 
eluent; lane 9, 800 mM imidazole eluent; lane 10, 1000 mM imidazole eluent. 
2.2. Conjugation of HR9 and Pep-1 to NfnB-Cys 
CPPs can be non-covalently conjugated to a wide range of materials [30,32–38]. One of the aims 
of this work was to attempt to improve the cellular uptake of the NfnB-Cys into cells, conjugation of 
CPPs onto the NfnB-Cys could aid in this process. CPPs were conjugated onto the NfnB-Cys at 
varying ratios. A further aim is to conjugate the NfnB-Cys onto AuMNPs which act as the delivery 
vector for our DEPT method, however, it needed to be established if the CPPs could interact with the 
NfnB-Cys without causing any negative effect. To look for proof of binding of the CPPs HR9 and 
Pep-1 to NfnB-Cys, native agarose (1%) gels were performed, with images of the stained gels shown 
in Figure 2 with the free NfnB-Cys, free CPP, and NfnB-Cys:CPP conjugate migration through the 
gels being analysed. A common feature of many CPPs is their cationic charge, therefore if the CPPs 
bind to the NfnB-Cys, the charge will differ from that of free NfnB-Cys, with the conjugates 
differently migrating through the agarose gel. As seen in Figure 2A, HR9 is positively charged, shown 
by migration towards the anode, whilst free NfnB-Cys is negative, shown by migration towards the 
cathode. Migration of the NfnB-cys-HR9 conjugates is retarded through the gel resulting in a streaked 
pattern. Similarly, as seen in Figure 2B, the Pep-1 CPP is also positively charged and migrates to the 
anode, whilst the NfnB-Cys:Pep-1 conjugates, are again retarded through the gel, particularly at 
higher Pep-1 ratios (1:5, 1:10, and 1:15). A similar effect can be seen in the 1:15 ratio of NfnB-Cys 
conjugated with HR9, although it is not as pronounced as the effect seen with Pep-1. 


















Figure 1. SDS-PAGE gel of the genetically modified nitroreductase (NfnB-Cys) purification using metal
ion affinity chromatography (IMAC): lane 1, protein ladder (Thermoscientific PageRuler 15–170 kDa);
lane 2, flow-through after applying supernatant to column; lane 3, flow-through after applying 10 mM
imidazole to column; lane 4, 50 mM imidazole eluent; lane 5, 100 mM imidazole eluent; lane 6, 200 mM
imidazole eluent; lane 7, 300 mM imidazole eluent; lane 8, 500 mM imidazole eluent; lane 9, 800 mM
imidazole eluent; lane 10, 1000 mM imidazole eluent.
2.2. Conjugation of HR9 and Pep-1 to NfnB-Cys
CPPs can be non-covalently conjugated to a wide range of materials [30,32–38]. One of the aims
of this work was to attempt to improve the cellular uptake of the NfnB-Cys into cells, conjugation
of CPPs onto the NfnB-Cys could aid in this process. CPPs were conjugated onto the NfnB-Cys at
varying ratios. A further aim is to conjugate the NfnB-Cys onto AuMNPs which act as the delivery
vector for our DEPT method, however, it needed to be established if the CPPs could interact with
the NfnB-Cys without causing any negative effect. To look for proof of binding of the CPPs HR9
and Pep-1 to NfnB-Cys, native agarose (1%) gels were performed, with images of the stained gels
shown in Figure 2 with the free NfnB-Cys, free CPP, and NfnB-Cys:CPP conjugate migration through
the gels being analysed. A common feature of many CPPs is their cationic charge, therefore if the
CPPs bind to the NfnB-Cys, the charge will differ from that of free NfnB-Cys, with the conjugates
differently migrating through the agarose gel. As seen in Figure 2A, HR9 is positively charged, shown
by migration towards the anode, whilst free NfnB-Cys is negative, shown by migration towards the
cathode. Migration of the NfnB-cys-HR9 conjugates is retarded through the gel resulting in a streaked
pattern. Similarly, as seen in Figure 2B, the Pep-1 CPP is also positively charged and migrates to the
anode, whilst the NfnB-Cys:Pep-1 conjugates, are again retarded through the gel, particularly at higher
Pep-1 ratios (1:5, 1:10, and 1:15). A similar effect can be seen in the 1:15 ratio of NfnB-Cys conjugated
with HR9, although it is not as pronounced as the effect seen with Pep-1.
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Figure 2. Agarose gels of the NfnB-Cys enzyme conjugated with HR9 (A) and Pep-1 (B). Gels have 
unconjugated NfnB-Cys in lane 1, increasing ratios of NfnB-Cys:cell-penetrating peptides (CPPs) in 
lanes 2, 3, 4, 5, 6, and 7 of 1:0.1, 1:0.2, 1:1, 1:5, 1:10, and 1:15 respectively, and unconjugated CPP in the 
lane 8. 
2.3. NfnB-Cys and NfnB-Cys:CPP Conjugate Reactivity to CB1954 
The genetically modified NfnB-Cys enzyme reactivity towards the prodrug CB1954 has 
previously reported by Gwenin et al. [14,39]. The addition of a Cys-tag was shown not to negatively 
affect enzymatic activity [28], but the conjugation of the CPPs onto the NfnB-Cys may influence 
enzyme reactivity towards CB1954. For this reason, NfnB-Cys:CPP conjugates were analysed for their 
CB1954 reactivity and compared relative to the free NfnB-Cys enzyme, the data for which is 
presented in Figure 3. 
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enzymatic activity [28], but the conjugation of the CPPs onto the NfnB-Cys may influence enzyme
reactivity towards CB1954. For this reason, NfnB-Cys:CPP conjugates were analysed for their CB1954
reactivity and compared relative to the free NfnB-Cys enzyme, the data for which is presented in
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Figure 3. The change in absorbance at 420 nm over 15 min for NfnB-Cys conjugated with varying
ratios of HR9 (blue) or Pep-1 (orange) (wt:wt). The reactions were carried out in the presence of NADH
(1200 µM) and CB1954 (1000 µM).
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When NfnB-Cys was conjugated with HR9 at varying ratios, hydroxylamine product formation
could still be seen at 420 nm, however, there appeared to be a significant effect on product formation at
ratios above 1:1. The experiment was repeated for NfnB-Cys:Pep-1 conjugates and no major effect
on product formation was seen for all ratios tested. Kinetic parameters were then determined by
generating a Michaelis–Menten profile for the conjugates (Table 1).
Table 1. Michaelis–Menten kinetic data obtained for NfnB-Cys and the conjugated NfnB-Cys with
HR9 and Pep-1 by varying the concentrations of the CB1954 prodrug in the presence of NADH as
the cofactor.
Conjugate Vmax (µMs−1) Kcat (s−1) Km (µM) Kcat/Km (µM−1s−1)
NfnB-Cys:HR9 7.98 ± 1.39 9.06 ± 0.82 3443 ± 916 0.00263 ± 4.6 × 104
NfnB-Cys:Pep-1 7.43 ± 1.25 8.44 ± 0.73 2381 ± 695 0.00354 ± 6.5 × 104
The comparison of the NfnB-Cys:CPP conjugates with our previously reported free NfnB-Cys
enzyme kinetics [29] and indicated an alteration in the enzyme’s kinetic behaviour, for both
NfnB-Cys:CPP conjugates. The kcat and Km values presented are the apparent (app) values measured
at 400 µM NADH. The CPPs decreased efficiency of NfnB-Cys; kcat/Km = 0.0026 µM−1s−1 for
NfnB-Cys:HR9 and 0.0033 µM−1s−1 for NfnB-Cys:Pep-1, compared to kcat/Km = 0.011 µM−1s−1
for NfnB-Cys). The reaction parameters had to be modified to use a higher concentration of
NfnB-Cys:HR9/Pep-1 to obtain full kinetic profiles of the conjugates, due to prodrug cost, therefore only
the kcat/Km constant can be directly compared between the NfnB-Cys enzyme and the NfnB-Cys:CPP
conjugates. In comparison the NfnB-Cys:HR9 shows a slightly higher product turnover compared to the
NfnB-Cys:Pep-1conjugate (kcat(app) = 9.1 s−1 and 8.4 s−1 respectively), however, the NfnB-Cys:Pep-1
demonstrates a higher affinity than NfnB-Cys:HR9 for the CB1954 (Km(app) = 2400 µM and 3400 µM
respectively). These results show that when conjugated to the CPPs; HR9 and Pep-1 at a 1:1 ratio
NfnB-Cys has a 65–74% decrease in kinetic efficiency. These results are presented in Table 1.
2.4. HPLC Profiles of NfnB-Cys and NfnB-Cyse:CPP Reaction Products
Previously we have shown that after a 30 min reaction time, NfnB-Cys reduced CB1954 to two
products (namely 2-NHOH and 4-NHOH) at a ratio of 32:68 respectively [29]. Following the same
procedure, conjugates of NfnB-Cys and the CPPs at a 1:1 molar ratio were tested for their ability
to reduce CB1954. Reaction product ratios were established, with the 4-NHOH product eluting at
approximately 5 min and the 2-NHOH eluting at 10 min [29,39]. The product ratios obtained for the
reactions between NfnB-Cys:CPP conjugates and CB1954 are presented in Table 2; the NfnB-Cys:HR9
produced products at a ratio of 36:64 (2’-NHOH vs 4’-NHOH), whilst the NfnB-Cys:Pep-1 produces
the 2-NHOH and 4-NHOH at a ratio of 35:65.
Table 2. The ratio of the CB1954 hydroxylamine derivatives formed when NfnB-Cys:CPP conjugates




2.5. Effect of NfnB-Cys and NfnB-Cys:CPP Conjugate on Cell Viability
Cell viability of SK-OV-3 cells presented as percentage cell survival was determined using
an increasing concentration of NfnB-Cys and NfnB-Cys:CPP conjugate and a constant CB1954
concentration (10 µM). Cells were incubated with medium, prodrug, and enzyme separately as
controls. NfnB-Cys was tested for its ability to induce cell death by the reduction of CB1954. This
combination showed an average cell viability of 80% at an NfnB-Cys treatment concentration of 200 nM,
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with the full results shown in Figure 4. Next, the NfnB-Cys:HR9 and NfnB-Cys:Pep-1 conjugates were
also tested for their ability to cause cell death, and compared relative to free NfnB-Cys, again full
results are displayed in Figure 4.
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Figure 4. The percentage cell survival of SK-OV-3 cells after 4 h incubation with: cell culture medium only,
10 µM CB1954 only, 200 nM NfnB-Cys only, 200 nM NfnB-Cys:CPP only, and increasing concentrations
of either; NfnB-Cys (blue), NfnB-Cys:HR9 (orange), or NfnB-Cys:Pep-1 (grey) (25–200 nM) in the
absence of NADH. Data points determined to be statistically significant by Dunnett test are marked
with a *. All data points represent at least three repeats and error bars indicate ± 1 standard deviation.
At each concentration tested, the NfnB-Cys:HR9 conjugates (25–200 nM) appear to be more
effective at causing cell death compared to NfnB-Cys alone (on average by 15%). Neither Pep-1 nor HR9
CPPs conferred any direct cytotoxicity towards SK-OV-3 cells. These results suggest that NfnB-Cys
conjugates exhibited a greater endocytotic potential, because, as shown from the kinetic experiments,
cell kill could not be attributed to enhanced enzyme efficiency. The data were analysed for statistical
significance by F-test with all data sets demonstrating levels of statistical significance (P < 0.005),
with the individual data points being analysed using the Dunnett test. Data points marked with a *
exceeded the Dunnett critical value indicating statistical significance.
2.6. Effect of AuMNPs and AuMNP Conjugates on Cell Viability
NfnB-Cys has been shown to successfully conjugate onto AuNPs [14], therefore it was considered
highly probable the same would be observed when conjugating onto AuMNPs. Conjugation of
NfnB-Cys onto AuMNPs was assessed by UV-Vis, Figure 5 is the overlay of UV-Vis scans between 450
and 650 nm. Here it is observed th t post conjugation the λ-max of the gold peak has increased by
4 nm from 536 to 540 nm, a indication of succe sful conjugation.
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There was a concern that, while performing the MTT assay on the AuMNPs, any exposed iron 
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Figure 5. Full-spectrum (450–650 nm) UV-vis spectrum of gold-coated superparamagnetic iron oxide
nanoparticles (AuMNPs) before (blue) and after (orange) conjugation with NfnB-Cys at a rati of 1:270
of AuMNP:NfnB-Cys. Scans were taken 48 h apart.
There was a concern that, while performing the MTT assay on the AuMNPs, any exposed iron
nanoparticles would cause excess oxidation of the TT yielding a bias on the final cell viability
percentage [40,41]. A brief experiment was performed to assess if the AuMNPs would cause excess
oxidation of the MTT causing a result bias. The AuMNPs caused a large excess of oxidation of the MTT
indicating a different cell culture assay would be required (data not shown). Due to this, the calcein
assay was selected as it requires the use of cellular esterase’s to convert calcein-AM into the fluorescent
calcein, an initial test showed the AuMNPs are not able to reduce calcein-AM to calcein indicating the
assay could be used without the risk of an experimental bias (data not shown). Figure 6 is the cell
viability results of cells treated with: AuMNPs, AuMNP:NfnB-Cys, or AuMNP:NfnB-Cys:HR9, here
the range of concentrations examined are the same as the cell viability experiments not containing
AuMNPs that are described in Sections 2.5, 3 and 4.7.
The AuMNPs do not demonstrate any direct toxicity towards the SK-OV-3 cells. As expected,
when AuMNP:NfnB-Cys and AuMNP:NfnB-Cys:HR9 conjugates were treated onto cells, there was
cell kill, which was taken to be the NfnB-Cys reducing the CB1954 due to the lack of toxicity presented
in the conjugated control samples. Here once again the conjugates with the HR9 do present a slightly
better cell kill overall than the AuMNP:NfnB-Cys, however the increase in the cell kill is minimal at
best. The data were analysed for statistical significance by F-test with all data sets demonstrating levels
of statistical significance (P < 0.005). The Dunnett test could not be performed to determine individual
data points statistical significance due to the low number of concentrations tested.
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Figure 6. The percentage cell survival of SK-OV-3 cells after 4 h incubation with: cell culture
medium only, 10 µM CB1954 only, 200 nM AuMNP only, 200 nM AuMNP:NfnB-Cys only, or 200 nM
AuMNP:NfnB-Cys:CPP only as control wells. Reaction wells contained increasing concentrations of
either; AuMNP (blue), AuMNP:NfnB-Cys (orange), or AuMNP:NfnB-Cys:HR9 (grey) (25–200 nM) in
the absence of NADH. Complete reactions also contain CB1954 at a 10 µM concentration. All data
points represent at least three repeats and error bars indicate ± 1 standard deviation.
2.7. Darkfield Imaging
Enhanced darkfield imaging was performed on SK-OV-3 cells treated with either: Dulbecco’s
modified eagle medium (DMEM), AuMNP, AuMNP:NfnB-Cys, or AuMNP:NfnB-Cys:HR9, with
the HR9 at a 1:1 ratio with the AuMNP. Treatments were done to assess cell uptake of the
nanoparticle/nanoparticle conjugates and if the addition of the HR9 aided in increasing cellular
uptake. On the basis that the HR9 conjugates appeared to be superior in cell culture testing as an
isolated conjugate, only the NfnB-Cys:HR9 combination was progressed to AuMNP testing. Figure 7
is the enhanced darkfield imaging of these slides, Figure 7A is the imaging of cells treated with just
DMEM to act as a control, with the cell nucleus stained blue with DAPI. The untreated control cell
(panel A) acts as a negative in relation to AuNP internalisation, to which any changes in terms of
particle intensity are compared following treatment with AuMNPs. Figure 7B–D are images taken
of cells treated with AuMNP, AuMNP:NfnB-Cys, or AuMNP:NfnB-Cys: HR9 respectively, again the
cell nuclei are counterstained blue with DAPI. These images have a higher frequency of intense areas
within the cells, which are absent when compared to control cells, potentially representing the presence
of AuMNPs within the cells. The increased bright areas within the cells in the images indicate that
the AuMNPs have internalized into the SK-OV-3 cells and when conjugated with NfnB-Cys, has
an increase in internalized nanoparticles. However, the AuMNP has a significant enhancement in
nanoparticle internalization when conjugated with a CPP, shown in Figure 7D.
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(DMEM), AuMNP, AuMNP:NfnB-Cys, or AuMNP:NfnB-Cys:HR9, with the images for each presented
in (A), (B), (C), and (D) respectively. The cells were treated with DAPI as a co-stain for imaging of the
cell nucleus. The scale bar is 25 µm.
3. Discussion
Since their initial discovery in 1988, CPPs have presented as a unique tool for aiding in the
uptake and delivery of a range of cargoes for medical applications. Literature shows that CPPs bind
non-covalently to specific cargo [36,42–44], the initial work was to determine whether HR9 and Pep-1
could also non-covalently conjugate with our enzyme as a majority of other studies focus on conjugation
with inorganic substances such as quantum dots. Conjugation success was confirmed, showing that
both HR9 and Pep-1 conjugates significantly alter the electrophoretic migration of NfnB-Cys through
the gel (Figure 2A,B) [45]. The HR9 peptide had a greater influence on NfnB-Cys migration, compared
to Pep-1, possibly a result of possessing a greater positive charge, caused by the large number of
cationic arginine residues [44], nine of which are found in the HR9 CPP [36,46], compared with the one
arginine residue found within the Pep-1 [46].
The high positive charges that CPPs possess could present a possible problem in terms of
interactions with the physical structure of proteins, this becomes a potential issue for enzyme
conjugation as it has previously been established that changes to the physical structure of the NfnB
enzyme can cause a change in the product ratio formed when the enzyme is reacted with the CB1954
prodrug [28]. Analysis by HPLC of the product ratio formed for the NfnB-Cys:CPP conjugates showed
little to no change from the free NfnB-Cys enzyme (ratio 32:68). NfnB-Cys:HR9 produced a ratio
of 36:64, whilst NfnB-Cys:Pep-1 produced a ratio of 35:65. The fact that the CPPs do not heavily
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influence the product ratio formed here indicates that the CPPs are not causing any major alteration
to the physical structure of the NfnB-Cys enzyme when they conjugate with it. This is important as
it means that the enzyme can still convert the CB1954 into its pharmaceutically active form without
CPP interference. A concern that would limit the efficacy of this treatment is that the CPPs are
non-covalently bound with the AuMNP:NfnB-Cys conjugate, which could dissociate when introduced
to a patient. Stability studies were carried out on AuMNP:NfnB-Cys:CPP conjugates (data not shown)
in the cell culture media used in the experiments discussed in this paper. The conjugates were left at
37 ◦C to simulate physiological conditions and were stable at up to and including 120 h which would
be a semi-realistic representation of treatment time.
As seen from the HPLC experiment, conjugated CPPs had no real effect on the product ratio
of NfnB-Cys, however, establishing if CPP conjugation caused an alteration in enzyme kinetics was
essential before progressing. As mentioned in Section 2.3, only the efficiency constant (kcat/Km µM−1s−1)
can be directly compared between the free and conjugated NfnB-Cys. When looking at the Kcat/Km
of the free NfnB-Cys, a value of 0.018 µM−1s−1 has previously been reported [29]. Both the kcat/Km
values for the NfnB-Cys:CPP conjugates show a significant drop in their efficiency, with NfnB-Cys:HR9
having a value of 0.0026 µM−1s−1 which is 4-fold less than NfnB-Cys and NfnB-Cys:Pep-1 having a
kcat/Km of 0.0035 µM−1s−1, a value almost 3-fold lower than NfnB-Cys. Therefore, while the earlier
experiments showed very little change in both product ratio and product formation, the efficiency of
both conjugates and product turnover has dramatically reduced compared to free NfnB-Cys. It is likely
that the change in enzymatic efficacy is not detected in the earlier experiments as UV-Vis absorbance
measurements were collected at 15 min, and the HPLC reaction time point was 30 min. However,
enzymatic kinetic experiments captured a short time frame, calculated over a 20 s time period. It is
likely that whilst the shorter kinetic experiments represent an accurate kinetic picture of the enzyme,
the longer experiments possibly indicate a more realistic scenario of the final concentration of products
produced as it allows for full reduction and consumption of prodrug. This drastic change in efficiency
of the conjugate compared to the free NfnB-Cys does raise a question that requires further research
to understand: If the HPLC indicates that the ratio of products formed does not largely differ from
the ratio formed by the free NfnB-Cys why does the kinetic data show such a difference? This might
indicate that the CPPs have some sort of interaction with the active site of the NfnB-Cys, it may be that
there is some slight blockage of the active site, or the CPPs cause a delay in the release of the products
from the active site. Further experiments are needed to answer this anomaly in the data.
When examining the NfnB-Cys:CPP conjugates in cell viability assays, there is an observable
improvement in the ability of the NfnB-Cys:CPP conjugates to induce cell death over free NfnB-Cys.
No additional NAD(P)H was added during the experiments, this was done so that the only cofactor
available for the enzyme would be found intracellularly within the SK-OV-3, meaning that the enzyme
has to be internalized along with the CB1954 to reduce the prodrug. This increased cell death, and
indicates that the addition of CPPs onto the enzyme aids the uptake of the enzyme, allowing the
increased cell kill despite the lowered enzymatic efficiency observed. The lower concentration range
of NfnB-Cys:HR9 tested in cell culture presents a low cell viability, this can be potentially attributed
to the hormetic effect [47], and may indicate a treatment concentration of 25 nM NfnB-Cys:HR9 as a
better option compared to the 200 nM treatment concentration.
The NfnB-Cys is intended for use in our patented MNDEPT [27], so in order to assess cellular
uptake of the enzyme, it was covalently conjugated to the AuMNPs and assessed for its viability as a
delivery vector, further conjugating HR9 with the AuMNP:NfnB-Cys and measuring the ability to
cause cell death. The cell viability results of the AuMNP trials presented in Figure 6 indicate that the
AuMNPs and the AuMNP conjugates do not themselves have an adverse toxic effect on the SK-OV-3
cells, from this it can be reasoned that any cell kill present is from the AuMNPs/AuMNP conjugates
that are able to internalize into the cells along with CB1954. Both of the conjugates tested were able
to reduce CB1954, shown by the decrease in cell viability which became more pronounced with the
increasing concentration dose.
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At each concentration tested, the conjugate with HR9 attached does show an increase in the cell
kill. However, this increase is very small, at a maximum 5–10%. This may indicate that either the
ratio of HR9 used for the treatment needs to be increased to achieve a higher internalization rate of
conjugates. It can also indicate that HR9 is not able to effectively internalize the AuMNP, meaning
a different CPP might present as a better option. It is also possible that all the cell culture data has
varying degrees of endosomal trapping, preventing the enzyme from fully reducing the prodrug within
the cells, in which case the CPPs may need slight modification to achieve endosomal escape either
with the use of an endosomolytic agent or a way to reverse high-affinity binding to cell receptors [48].
Furthermore, uptake efficiency of CPPs into cells can vary based on cell type, here the cell line SK-OV-3
showed CPP uptake, however it must be considered that other cell types may show much more limited
uptake or no uptake at all. Along with this further work to be done would involve examining the
potential lysosomal trapping and to assess colocalization of the nanoparticle conjugates within the
cellular structures.
Darkfield imaging was performed on the three nanoparticle/nanoparticle conjugates to assess
if the conjugation of either the NfnB-Cys and/or the HR9 increases the cellular internalization of the
nanoparticle. Darkfield imaging allows us to visually inspect cells, and view nanoparticles that are
associated within the cell, here imaging was performed in an attempt to assess what observable change,
if any, the addition of a CPP onto the conjugate had on the cellular internalization of the conjugate. It is
observable that the addition of the NfnB-Cys onto the AuMNP causes more nanoparticles to internalize
into the cells, compared with unconjugated AuMNP. This is important as it shows that even without
the CPP, the AuMNP:NfnB-Cys conjugate can penetrate into the cells, reinforcing that AuMNPs are a
viable choice for use in MNDEPT. The more notable difference is observed with the incorporation of a
CPP onto the conjugate. This addition allows a drastically larger number of conjugates to internalize
into the cells, indicating that the CPP is being successful in its role.
In conclusion, two different CPPs have been successfully conjugated to the genetically modified
NfnB-Cys enzyme at a 1:1 ratio. The HPLC reaction profiles of the NfnB-Cys:CPP conjugates have been
described, showing a slight change from the ‘free’ NfnB-Cys enzyme’s product ratio. Kinetic profiles
have been established for the conjugates at a 1:1 ratio showing a large drop in the conjugate’s kinetic
efficiency. However, when the conjugates are tested in cell viability assays an increased cell kill is
observed, consistent with what would be expected with an increased uptake of the enzyme, whilst the
CPPs themselves show no observable toxicity. Cell viability assays were also performed on AuMNP,
AuMNP:NfnB-Cys, and AuMNP:NfnB-Cys:HR9 conjugates, and the AuMNPs themselves had no
observable toxicity towards the cells whilst the other tested conjugates demonstrated an increasing
cell kill with increasing treatment concentration. Finally, darkfield imaging presents an increased
internalization of AuMNP conjugated when HR9 is also conjugated with the AuMNP:NfnB-Cys, which
is consistent with the increased cell kill seen on the AuMNP:NfnB-Cys:HR9 conjugate.
4. Materials and Methods
All chemicals were supplied from Fisher Scientific, UK and Sigma Aldrich, UK unless stated
otherwise.
4.1. Expression and Purification
An nfnb-cys gene that had been previously cloned into the pET28a(+) (Novagen, Merck, UK)
expression vector [14], was transformed into an E.coli Rosetta strain B21 DE3 (Novagen, Merck,
UK) and the expression and purification of the NfnB-Cys enzyme was carried out as previously
described [14]. Briefly, a colony of E. coli Rosetta containing the expression vector (previously confirmed
using gel electrophoresis, data not shown) with the nfnb-cys gene was added to a Luria-Bertani
(LB) inoculant tube (5 mL) also containing kanamycin (50 µg/mL). This was vortexed at 1500 rpm
overnight for 16 h. Following this the inoculant was added to a flask containing LB expression medium
(500 mL) and kanamycin (50 µg/mL). The bacterial medium was left to grow to an optical density
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of 0.6–0.7 measured at 590 nm, after which expression of protein was induced by the addition of
isopropyl-β-D-thio-galactoside (IPTG) (2 mL, 100 mM). After 4 h of NfnB-Cys expression, the culture
was centrifuged (9318 rcf, 10 min, 4 ◦C) and cell contents released by firstly suspending the bacterial
pellet in imidazole (10 mM, pH 7.2) and then sonicated on ice for 2 min at 40% amplitude, using
30 s bursts. Cell debris was removed by high-speed centrifugation (44,800 rcf, 1 h) and the yellow
supernatant passed through a metal ion affinity chromatography column using Ni2+, with imidazole as
the eluent. NfnB-Cys protein eluted as yellow fractions that were collected and incubated with flavin
mononucleotide (FMN) on ice for 1 h to ensure cofactor saturation. The saturated solution was then
subjected to PD10 size exclusion chromatography (SEC) to remove both impurities and any residual
imidazole eluent, before the NfnB-Cys enzyme was collected in phosphate buffer (50 mM, pH 7.2).
The molecular weight and purity of the protein fractions were assessed using 12% SDS-PAGE and
visualized using Coomassie blue stain. The concentration of the protein was established using the
Bradford assay using a standard BSA curve, according to the manufacturer’s instructions.
4.2. CPP Conjugation to NfnB-Cys
Conjugation of the CPPs, HR9 (CHHHHHHRRRRRRRRRHHHHHHC) and Pep-1
(KETWWETWWTEWSQPKKKRKV), to the NfnB-Cys enzyme was performed as described for
conjugation onto quantum dots (QD) by Liu et al. [36], and replacing the QD with our NfnB-Cys. This
was done by mixing the enzyme and CPP in a silinated Eppendorf at various wt:wt ratios (1:0.1, 1:0.2,
1:1, 1:5 1:10, 1:15). The enzyme: CPP mix was then incubated at 37 ◦C for 30 min and assessed for
conjugation via agarose gel electrophoresis.
4.3. Confirmation of CPP Conjugation to NfnB-Cys
A 1% (w/v) agarose gel was prepared by dissolving agarose (1 g) in 100 mL TBE buffer (Tris-HCl;
54 g, Boric acid; 27.5 g, EDTA; 20 mL, 500 mM dissolved in H2O 1 L, pH 8) [14]. The gel was then
submerged in 1× TBE running buffer and the comb removed. NfnB-Cys:CPP conjugate (20 µL) was
mixed with 20 µL of a 2× loading dye (10 mM Tris-HCl pH 6.8, 2% SDS, 0.01% Bromophenol blue, 20%
glycerol) [45,49] and loaded onto the gel. Unconjugated NfnB-Cys and CPP were used as controls. The
gel was then run at 100 V for 1 h, and visualized using Coomassie blue stain.
4.4. NfnB-Cys and NfnB-Cys:CPP Conjugate Activity to CB1954
NfnB-Cys:CPP conjugates and unconjugated NfnB-Cys were assessed for their reactivity to CB1954
by incubating NfnB-Cys (25 µg/mL) or NfnB-Cys:CPP (25 µg/mL, with volume added adjusted for
additional CPP in the mixture to ensure 25 mg/mL of NfnB-Cys) with NADH (300 µM), phosphate
buffer (PB) (50 mM, pH 7.2), and CB1954 (100 µM). Absorbance spectra (200–800 nm) were measured
every 90 s for 15 min on a Jasco V-550, UV-vis spectrophotometer. Standard control scans were also run
on the NADH, enzyme, enzyme:CPP conjugate, prodrug, and CPP with NADH and CB1954 to ensure
the CPPs could not reduce the prodrug.
4.5. CB1954 Kinetics
CB1954 kinetic experiments were all carried out in a 96-well microtiter plate (Corning, USA) using
a Thermoscientific Varioskan 96-well plate microplate reader [29]. Product formation at 420 nm was
measured over time in order to determine the Michaelis–Menten kinetic parameters of CB1954 against
the NfnB-Cys:CPP conjugate. CB1954 (0.1–5 mM), NADH (400 µM) and PB (50 mM, pH 7.2) were
combined and incubated at 37 ◦C for 3 min before purified NfnB-Cys or NfnB-Cys:CPP (1:1 ratio) was
added (50 µg/mL; again NfnB-Cys:CPP volume added was adjusted to ensure 50 µg/mL of NfnB-Cys
was added). Dimethyl sulfoxide (DMSO) solvent concentration was kept constant at 5% v/v to account
for any negative solvent related effect [50]. Hydroxylamine yield per second was determined by
calculating the change in absorbance over 20 s and the molar extinction coefficient, which is the same
for both products (ε = 1200 M−1cm−1 at 420 nm) [14,18,39,50–53]. Data gathered was transferred to
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SigmaPlot 12 (SPSS, Systat Software Inc.) where a non-linear regression tool was used to generate a
Michaelis–Menten hyperbolic curve and a report containing the kinetic information of the system.
4.6. HPLC
For HPLC analysis, a Dionex Ultimate 3000 HPLC machine Thermoscientific, USA was used with
a C18 column (Waters Spherisorb®5 µm ODS2 4.6 mm × 250 mm C18 column, UK). Experiments were
carried out at the following parameters: 50 µL injection volume, 25 ◦C column oven temperature, UV
detection wavelength of 420 nm, and a run time of 30 min [41,42].
HPLC samples were prepared as previously described [29,39]. Briefly, samples were prepared in
a 15 mL amber falcon tube (due to the light-sensitive nature of some of the reaction constituents) as
follows: NADH (120 µL, 10 mM) NfnB-Cys/NfnB-Cys:CPP (116 µg/mL, volume adjusted), CB1954
(20 µL, 50 mM) then made to a final volume of 1080 µL using PB (50 mM, pH 7.2). This mixture was
incubated at 25 ◦C for 15 min, and then degassed under nitrogen (g) for 15 min, giving a total reaction
time of 30 min. Next, 750 µL of the final de-gassed reaction was transferred to a chromacol select 2 mL
vial (2-SVW8-CPK) and placed into the HPLC machine. The solvent mixture was acetonitrile/water at
a 10:90 ratio, with the acetonitrile increasing at 1% per min. After 20 min, the acetonitrile concentration
was altered to keep increasing by 40% per minute which reached a concentration of 100% acetonitrile
after 22 min. Eluents were scanned at 420 nm with product peaks being identified against reagent
standards carried out using the same protocol: CB1954 (20 µL, 50 mM), NADH (120 µL, 10 mM), and
NfnB-Cys (116 µg/mL, volume adjusted for concentration of NfnB-Cys from purification). Ratios of
the 2’ and 4’-hydroxylamine products were determined at 420 nm, where both products have equal
absorbance [18].
4.7. Cell Viability Assays
Cell viability assays were performed as previously described [30]. SK-OV-3 (ECACC 91091004) cells
were seeded into a 96-well plate (Corning, USA) at a density of 1× 103 cells per well, in 100µL Dulbecco’s
modified eagle medium (DMEM) containing 10% FBS, 1% L-glutamine, and 1% penicillin-streptomycin
and allowed to attach to the plate overnight in a CO2 (5%) incubator at 37 ◦C. After 16 h, the media
was carefully aspirated off and fresh media containing increasing concentrations of 25 to 200 nM of
NfnB-Cys or NfnB-Cys:CPP conjugate (50 µL) was added to the wells along with CB1954 (100 µM).
Wells where only NfnB-Cys, NfnB-Cys:CPP conjugate (200 nM), CB1954 (10 µM) or DMEM (100 µL)
were added served as controls. After a 4 h incubation in a CO2 (5%) incubator at 37 ◦C, the treatment
media was carefully aspirated off and fresh media (100 µL) added. Cells were then left for 48 h in a
CO2 (5%) incubator at 37 ◦C, after which MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) (20 µL, 5 mg/mL) was added and then left for a further for 4 h at 37 ◦C. Culture media was
aspirated off and DMSO (100 µL) used to dissolve the purple formazan crystals. Finally, absorbance
was read at 570 nm using a Thermoscientific Varioskan Flash plate reader.
4.8. Preparation of AuMNP:NfnB-Cys and AuMNP:NfnB-Cys:HR9 Conjugates for Cell Culture and
Darkfield Imaging
Previously synthesised AuMNPs [54] were conjugated with NfnB-Cys following the published
method for conjugating NfnB-Cys onto gold nanoparticles [14]. Briefly, magnetically purified, 50 nm
AuMNPs suspended in sodium citrate dehydrate (1 mM, pH 7.4) were incubated with a volume of
NfnB-Cys at a ratio of 1 AuMNP:270 NfnB-Cys to achieve a monolayer coating of the nanoparticles.
The volume of NfnB-Cys incubated with AuMNPs was determined based upon the concentration
of NfnB-Cys determined by the Bradford assay and the concentration and size of AuMNPs as
determined by UV-Vis [14]. Nano-conjugates were left to form at 4 ◦C for 48 h. A full wavelength
UV-Vis scan (450–650 nm) was performed on AuMNPs before and after conjugation, with a change
in the gold peak being examined for. A redshift of 3–5 nm of the λ-max of the gold peak indicates
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successful conjugation [14,55]. AuMNP:NfnB-Cys:HR9 conjugates were prepared by incubating the
AuMNP:NfnB-Cys with HR9 at a 1:1 ratio of HR9 to AuMNP, at 37 ◦C for 30 min.
4.9. AuMNP Cell Viability Assays
The calcein assay was performed with AuMNPs and AuMNP conjugates. SK-OV-3 (ECACC
91091004) cells were seeded into a 96-well plate (Corning, USA) at a density of 1 × 103 cells per
well, in 100 µL Dulbecco’s modified eagle medium (DMEM) containing 10% FBS, 1% L-glutamine,
and 1% penicillin-streptomycin and allowed to attach to the plate overnight in a CO2 (5%) incubator
at 37 ◦C. After 16 h, the media was carefully aspirated off and fresh media containing increasing
concentrations of 25 to 200 nM of AuMNPs, AuMNP:NfnB-Cys, or AuMNP:NfnB-Cys:HR9 (50 µL)
was added to the wells along with CB1954 (100 µM). Wells where only AuMNP, AuMNP:NfnB-Cys
AuMNP:NfnB-Cys:CPP conjugate (200 nM), CB1954 (10 µM), or DMEM (100 µL) were added served
as controls. After a 4 h incubation in a CO2 (5%) incubator at 37 ◦C, the treatment media was carefully
aspirated off and fresh media (100 µL) added. Cells were then left for 48 h in a CO2 (5%) incubator
at 37 ◦C, after which the media was carefully aspirated off and 1× calcein DW buffer (100 µL) was
added to each well. This was again carefully aspirated off after which 1× calcein DW buffer (50 µL)
and 2× calcein AM (50 µL) were added to each well. The plate was then incubated for 30 min in a CO2
(5%) incubator at 37 ◦C. The fluorescence of the sample was measured using an excitation/emission
filter of 495/515 nm using a Thermoscientific Varioskan Flash plate reader.
4.10. Darkfield Imaging
Darkfield imaging was performed using CytoViva enhanced darkfield imaging. SK-OV-3 cells
were seeded onto 8-well Thermo Scientific™ Nunc™ Lab-Tek™ II Chamber Slide&trade glass slides at
a density of 1 × 104 cells per well. Sub-confluent cells (~80%) were treated with either DMEM media as
a control, unconjugated/‘naked’ AuMNPs, AuMNP conjugated with NfnB-Cys at a ratio of 1:270 of
AuMNP:NfnB-Cys, or AuMNP:NfnB-Cys conjugated with HR9, with the CPP conjugated at a ratio of
1:1 with the AuMNP:NfnB-Cys conjugates. Cells were incubated with complexes for 4 h before the
treatment media was removed and cells washed twice with DPBS, removing loosely associated external
nanoparticles [56–60]. Cells were then fixed using 3.7% formaldehyde and mounted using Vectashield
containing 4′,6-diamidino-2-phenylindole (DAPI) (Vector labs), counterstaining the nucleus.
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